

Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)

Meeting – March 11, 2020 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Skrepnek

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 12, 2020 DUR Minutes – Vote
- B. February 12, 2020 DUR Recommendations Memorandum

Items to be presented by Dr. Chandler, Dr. Adams, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – See Appendix B

- A. Pharmacy Helpdesk Activity for February 2020
- B. Medication Coverage Activity for February 2020
- C. SoonerPsych Program Update

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Xcopri® (Cenobamate) – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Tosymra™ (Sumatriptan Nasal Spray), Reyvow™ (Lasmiditan), and Ubrelvy™ (Ubrogepant) – See Appendix D

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Ratterman, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Esperoct® [Antihemophilic Factor (Recombinant), Glycopegylated-exei] – See Appendix E

- A. Introduction
- B. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize ProAir® Digihaler™ (Albuterol Sulfate Inhalation Powder) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Van, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Evenity® (Romosozumab-aqqg) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Asparlas™ (Calaspargase Pegol-mknl), Daurismo™ (Glasdegib), Idhifa® (Enasidenib), Lumoxiti® (Moxetumomab Pasudotox-tdfk), Tibsovo® (Ivosidenib), and Xospata® (Gilteritinib) – See Appendix H

- A. Introduction
- B. Product Summaries
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

11. Action Item – Vote to Prior Authorize Azedra® (Iobenguane I-131) – See Appendix I

- A. Introduction
- B. Azedra® (Iobenguane I-131) Product Summary
- C. Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

12. Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Aliqopa™ (Copanlisib), Brukinsa™ (Zanubrutinib), Polivy™ (Polatuzumab Vedotin-piiq), and Ruxience™ (Rituximab-pvvr) – See Appendix J

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Lymphoma Medications
- D. Prior Authorization of Lymphoma Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Lymphoma Medications

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Muchmore, Chairman:

13. Annual Review of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib) – See Appendix K

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
- D. Prior Authorization of Lutathera® (Lutetium Lu-177 Dotatate) and Vitrakvi® (Larotrectinib)
- E. Market News and Updates
- F. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. Annual Review of Multiple Sclerosis (MS) Medications and 30-Day Notice to Prior Authorize Mayzent® (Siponimod), Mavenclad® (Cladribine), and Vumerity™ (Diroximel Fumarate) – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of MS Medications
- C. Prior Authorization of MS Medications
- D. Market News and Updates
- E. Mayzent® (Siponimod) Product Summary
- F. Mavenclad® (Cladribine) Product Summary
- G. Vumerity™ (Diroximel Fumarate) Product Summary
- H. College of Pharmacy Recommendations
- I. Utilization Details of MS Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. 30-Day Notice to Prior Authorize Tepezza™ (Teprotumumab-trbw) – See Appendix M

- A. Introduction
- B. Market News and Updates
- C. Tepezza™ (Teprotumumab-trbw) Product Summary
- D. College of Pharmacy Recommendations

Items to be presented by Dr. Van, Dr. Muchmore, Chairman:

16. Annual Review of Anti-Emetic Medications – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Anti-Emetic Medications
- C. Prior Authorization of Anti-Emetic Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anti-Emetic Medications

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

17. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix O

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

- A. Annual Review of Pharmacy Benefit
- B. Anti-Diabetic Medications
- C. Antihypertensive Medications
- D. Lung Cancer Medications

**Future business subject to change.*

19. Adjournment